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Malignant melano m a ce ll s possess a unique biochemical 
pathway that converts L-3,4-dihydro xy phenylalaninc (L-
do pa) to the biopigm ent m elanin. Selective cy totoxic in-
corpo ration o f exogenous L-dopa into m elano m a cell s in 
vivo may provide a m eans of desig ning specific chemo-
therapeutic agents useful in the trea tment of thi s disease. 
U sin g the Harding-Passey murine m elanotic tumo r model , 
a preferential uptake of [3H)L-dopa by the tumor was char-
acterized. Following pretreatment of the tumor-bearing m.icc 
with nonradioactive L-dopa , a signifi cant enh ancement 
L-3,4- Dihydroxyphenylalanine (L-dopa) is a precursor in the biosynthesis of mel anin [1 ,2]. M ali gnan t melanoma , still a therapeutica ll y res istant tum o r, possesses this unique biochemical pathway for the conversion of L-do pa to melanin [3 ,4]. Severa l inves ti ga to rs have used this spe-
cial pathway as a m eans to design m o re effecti ve chem o thera-
peutic agents useful in the t reatment of this di sease. Wi ck et al 
[51 showed a selec tive cytotoxi c in co rpo ration of L-do pa by pig-
mented m elanoma cells in vitro . Blois and Kallman [6] demon-
strated a hi g hl y selec tive uptake of radioa ct ive L-dopa into a spon-
taneously arising murine melano ma. Recently, using the Harding-
Passey murin e melano ma model, o ur studi es and o thers were able 
to show an extensive loca liza tio n of L-do pa in the tumor and in 
the adrenal g lands [7,8]. In this communi catio n we describe a 
preferenti al localization of (3H] L-do pa in the H arding-Passey tu-
m o r following pretreatment of tum o r-bearin g mice with non-
radioactive L-dopa, and contrast it to th e conco mitant ti ssue dis-
tributio n and retentio n of this radioactive agent in the control 
animals. 
MATERIALS AND METHODS 
Experitnental Procedure CDF 1 mice used in this study were 
approx imately 3 months of age and weig hed on average 25 g. 
H ardin g-P assey pi g m ented melano m a tum or cells, prepared from 
tumo r transplant , were seria ll y passaged s.c. in CDF1 mice. The 
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(p < 0.01) of [3 H)L-dopa incorpo ration and retention inro 
m elanoma for a period of 24 h was o bserved , vvhen com-
pared with the concomitant tissue distribution and clear-
ance of radioactivity in the contro l anim als. This finding 
suggests that by initial pretreatment of m elan o m a with 
nonradioactive L-dopa, the subsequent selecti ve accumu-
lation of f3HlL-dopa in tumo r m ay provide a useful tool 
in tes ting new modalities of thcr:1py in mali gnant m ela-
noma. J l11vest D ermatol 86:560-562, 1986 
cell suspensio ns were made fro m excised tumors w hich were 
min ced and passed thro ug h 80-mesh stainless s teel screen in alpha-
m od ifi ca tion o f Eagle's minimal essenti al medium contain ing 3-
(N-mo rph o lin o) propane sulfuri c acid 4.08 g / liter. Each m o use 
was in oculated s . c. in the ri g ht groin with 1 X 106 tum or cell s. 
E ig ht days after transplantatio n of the tum o r, w hen the tum or 
nod ules· reached an average diameter of0.75-1. 0 em , the anim:ds 
were rando mly divided into 2 g ro ups of 8 mi ce each. The ex-
perimental g ro up receiv ed a s.c . injection of nonradi oactive L-
dopa (100 m g/ kg) in the o ppos ite g ro in w hile th e contro l g ro u p 
rece ived an equi valent volume (0.3 ml) of normal sa lin e s.c. One 
ho ur later 20 t-LC i (3H]L-do pa were admini stered to each m ouse 
i. p. The an imals of both g ro ups were sacrificed by etherization 
and exsa ng uination by ca rdiac puncture at 0.5 h , 1 h , 4 h , and 
24 h after injectio n of f3 H]L-dopa . The mi ce were dissected and 
ti ssues, includin g brain , lun g, spleen , adrena l g lands, kidney. 
muscles, and tumo r, were rem oved . Each specimen was weig hed 
and burned in a Packard Tri-ca rb oxidizer. The radioacti vity w as 
m easured in a liquid scintillatio n counter and fo r each ti ssue the 
counts were expressed in cpm / m g of wet ti ss ue weight. 
Statistical Analysis The objective w as to determ ine any di~ 
fercnce in the tim e course for each organ site between the cont rol 
and th e ex perimental g roups. For each site th e uptake and reten-
tion of f3H]L-d o pa were approximated as an exponential ti m e 
course. The linear form of this m odel is: 
In (C,) = In (Co) - Bt, 
where C, is the cpm/mg wet ti ssue of radioactivity at time t from 
initial inj ec tio n of !3H)L-dopa , B is the slope or retentio n rate , 
and C 0 is the cpm / m g wet tissue at time 0. Fits o f the data by 
linear reg ression of both pretreated and control g ro ups are given 
in Figs 1, 2, and 3A-F for the tum or, adrenal g lands, brain , lu ng . 
liver, spleen, kidney, and muscle, respectively. 
At each site the contro l and experimental groups were corn-
pared by eva luatin g the colinea rity of the reg ression lines. Stan-
dard stati stical m ethods were used with a partial F-test [9). In 
essence the 2 pretreatment g ro ups w ere tested for the sa m e re-
tenti on rate and the sa me initial uptake. 
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Fig 1 illu strates the tum or uptake and retentio n kin eti cs ofL-do pa 
after 20 J..~.C i i·' H [L-dopa were: injected i. p. into the H ardin g-Passey 
mela n o n1a rumor-bearing mi ce: w hi ch were g rouped by whether 
or not they had been pretreated with no nr,Jdi oact ive L-dopa. The 
rad ioactivity loca li zed was sig nifi ca1Hl y hi g her in the pretreated 
w mor th an in th e contro l tum o r (p < ().(1 1). Whereas the rad io-
activ it y r eta ined in th e contro l rumor cleared alm os t co mpletely 
at 24 h postinjecti o n , a st ro ng retenti o n was no ted in the: pretreated 
ru mor over 24 h . T his fi nding indi cated that pretrea tmen t of 
nonra di oacti ve L-do pa co uld enh ance the uptake of subseq uentl y 
adm ini s tered l.lH]L-d o pa by the tumor, and also co uld retard the 
clea rance of the rad ioactive: m elanin precurso r fro m m elan o m a. 
Fi g 2 s ho w s th e co nco mitant uptake and clearance kin et ics of 
L-dopa in the ad renal g land of th e H ardin g-Passcy mel ano m a 
rumor-bea rin g mi ce. Since L-dopa ha s been a precurso r and co m-
mon inte rm ediary in the biosyn thetic pathway o f mel anin , epi-
nephrine, and no repin ephrine [1 ,2J, an expected in crease in the 
rime course from th e pretreatment with non radi oactive L-dopa 
was o b se rved in the adrenal g land ( p < 0.05) [7.8]. H owever, 
the s lo p e of the time course fo r this ti ss ue was un affec ted by 
pre treattnent w ith the no nradioa ctiv e melanin precurso r (Fig 2) . 
The si n1u ltaneous uptake and retenti o n of IJHI L-dopa in the o th er 
vira l o r gans in cludin g the brai n, lun g, li ver, sp leen , kidne y, and 
m uscle were no t inAuen ced by this no nradi oactive L-d o pa pre-
trea tment (Fi g 3A-J~). O nl y the tum o r and the adrenal g land 
exhibited a sig nifica nt stat istica l difference between the time courses 
of the co ntro l and experimental pret reat m en t g ro ups (Fi gs I . 2) . 
In a dditi o n, the uprakc and retenti o n o f IJHIL-d opa a t each 
orga n s ite w n e co mpu ted as th e area unde r curve (AU_C) 11 01. 
us ing: 
AU C = ( x C,c u, dt = C,/ B. ), 
For each site th e uptake/ reten ti on effectiveness between the pre-
treated and con t ro l g ro ups was m easu red by a relative enh ance-
ment index (H E!) as foll ows: 
REJ = AU Cpn:tn:.H l'd - AU Cnmtrul . 
AUCt:untrul 
Table I presents the res ults g rouped by site and pretreatm ent. 
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Figure 1. T umo r uptake and retentio n kineti cs o f I3 H IL-dopa in pre-
trea ted (X) and contro l (0) 1-brdi ng-Passcy melano m a. Reg ress io n lines 
display the effect o f no nradioacti ve 1.-do pa pretreatmmt (so lid li11e) aga inst 
1hc control (da shed li11 e) ( p < 0.0 1). 
U PT AKE/RET ENTION OF 1- DOPA IN MELANOMA 561 
(:]; I 000 
E 
.......... 
E 
Q_ 
u 
:r: 
.., 
I 
<( 
Q 
0 
0 
I 
_J 
100 
0 
0- -
0 
---
---
8 12 16 
TIME (hr) 
-9 
0 
20 
Figure 2. Upt:tk c and clearance kinetics nf 1-'H IL-dopa in adrenal g land 
o f p retrea ted ( X ) and control (0) Hardi ng-Passcy m elano m a tumo r-
bearin g mice. Reg ression lines di spla y the dTect o f no nrad ioac ti ve L-dop.t 
prc lreatm cnt (so lid fi11 1') against the contro l (dashed li11 1') ( p < 0.05). 
The pret rea ted tum o r ex hibited the brges t rcl:ni ve enh ancem ent 
fa cto r (()_ %). 
These results sugges t th at w ith the selecti ve tim ed usc of L-
dop :J , a prefcremiall oc:J ii zati o n of [-'H[L-do pa co uld be o btain ed 
in the H ardin g- Passcy mel ano ti c tum o r. T hus, th e selective in-
co rpo rat io n o f 1-'H [L-dopa in m elano ma by initi al pretreatment 
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Figure 3. O rgan uptake and cleara nce kineti cs o ll'H IL-dopa in pretreated 
( x) and contro l (0) Harding-Passey melanoma tum o r-bl'orin g micl' : (A) 
Brai n , (B) lung. (C) li ver, (D) spleen, (t:l kidne y, and(/:) muscle. Hegrl's-
sion lines displa y the effecr of no nradioacti ve L-dopa pretrea tmcnr (so lid 
li11es) agai nst the contro l (dasht•d li11 cs). Each p kvel not sig nifi cant. 
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Table I. Area Unde r C urve (A UC) Comparis o n of L-Dopa 
Pretreatmen t Eftl:ct b y Org an Site 
AUC (cpm-h/ 111 g) Relati ve 
Enhan cc nH'ttt 
Site Pretreated Control Index 
Tuntor 12, \!l() 1.53 1 6. 'J6 
Adrena l gland 16,460 \1,454 ll.74 
BrJin 2.1!l7 I, HUS 0.21 
Lun g 3.(,63 3.1-14 0. 17 
Li ve r 4,000 3.255 0.23 
Spleen 2,45 1 2.423 0.0 1 
Kidne y 7.305 5,\1\!6 U.22 
Muscle 2,62!l 1,7 16 0.53 
A uc is co mputed rro m n.:g r<.:ss ion fa ror 131-t IL-dopa kinc.:tics. Nut~ th l' hi ghes t 
relati ve cnhnnctmcnt inJt·x fo r rumor. 
of tum or with nonradioa ct ive L-dopa ma y provide a m ea ns of 
studyin g and testing new modalities of therap y in this, otll: o f 
the most agg ress ive forms of ca ncer. 
DI SCUSS ION 
In the present study the Harding-Passey pi g memed mel ano m a 
tumor was chose n JS a m o del bccause of its similarity to human 
melan o nia w ith respect to irs response to chctnorherapy. T he 
H arding-l:'asscy mctmoma shows a response rate of 25% to da-
carbazim: treatm ent , whi le other experimen ta l melanom a tumors , 
e .g. , the 1:31 6 pigmented melanotic tumor, do not respond as well 
to daca rbazine 1111. 
Studies usin g radioacti ve melanin precursor as a tool have shown 
that the concentrat io n of radioa cti vit y found in various anima l 
melanom a tumors may vary !6,7, 12 1. T he ava ilable da ta suggest 
that this relative difference in in creased uptake and concen tration 
o f radioactivity in th e tumor is related to the rate of m elanin 
synthes is . 13lois and Kallman [6 1 fo und th at the radioact iv it y co n-
centration was p rimarily located in the melanin poly m er and not 
in the remainder of the rumor cell. Takahashi and Fitzpatri ck !1 2 ] 
found an absen ce o f stable dopa in the h ydrolysates of melano-
somes from deep ly pi g mcmed B 16 melanoti c tumors, but dis-
covered large con centratio ns o f stab le dopa in t he Hardin g- l'assc y 
melanoma. This wou ld tmd to also suppo rt th e proposa l of Bl o is 
and Kallm an !6 1 that the.: uptake.: and in corporati o n o f prc.:cursors 
such as dopa arc pro portiona l to the ra te of mel anin synthesis in 
the tum or. 
While.: most repo rts have shown that in creas in g melaniza ti o n 
and in co rporatio n of agents that enhance pigmentation can indu ce 
se lect ive.: toxicity to melanoma ce lls in vitro [3- 51, s tudies by 
Parsons and Morrison !1 3 1 suggest that this toxicity m a y be closely 
related to DNA damage. Although the pn:cisc mechanism of this 
DNA damage is nor known, the se lective preferential uptake of 
do pa and the resultin g toxicity to mammal ian cells docs corn: late 
well w ith mel anizat ion IS \. In additi o n , no inhibition by dopa o r 
dopamine agonists and antagon ists in amelanotic B16 ce ll s has 
been obse rved \1 4]. 
O ur findings sugges t that pretreatment of mice.: bearin g H ard-
ing-Passey m elanom a tum o rs w ith L-dopa docs enh an ce.: th e ac-
cumu lation of [31-1\ L-dopa in the tumor (Fig I). Conceptu all y , the 
avai lable dopa bindin g sites wo ul d have been sa turated by pre-
treated unlabeled dopa, and shou ld n:sult in a subsequent reduc-
tion in uptake or accumul atio n of radiolabeled L-dopa in the tu-
m o r. H oweve r, the inc reased uptake of J3 H IL-dopa ma y sugges t 
an altern ate pat hway for L-dopa m etabolism and melanin for-
m ati o n in melan o m a. The cyclic AMP sys te m ha s been identified 
as an altcmate path way for m e lan in sy nthesis \3, 15 \. Iva nov ct al 
[1 6] adm inistered nonradioactive L-dopa to mi ce bearing Hard-
in g-Passcy mel anotic tumor and found that the cycl ic AMP in 
the tumor tissue was hig her (p < 0.05) than that in the contro ls 
which were treated with [3H ]L-dopa alone. Further, the selective 
in creased uptake of radio labeled dopa in the H a rdin g-Passey mel-
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anoma (Fig I, Table I) fo ll owing prctrea tmcllt w ith un labeled 
dopa also confirm s the sa me findin g of another repo rt of mela-
noma tum o rs in ha m s ters and in a lbino mi ce 17 !. Altern a tively . 
L-do pa in co rpo rat io n of mel anoma m ay also be enhanced b y d opa 
deca rboxy lase inhibitio n. Wicket al!1 7 ! h ave sh ow n that in the 
presence o f a potellt decarboxy lase inhibito r , serum level of 
L-dopa could be elevated, th e reb y an enhan cement of L-dopa 
in co rpo rati o n into m ela noma was achieved and the diversi on of 
labe l into adrena l g land was g reatl y obviated. In o ur stu d y of 
ti ssue levels o f L-do pa in corpora tio n , no serum to organ- specific 
activ ity was dete rmined. A lt ho ug h the specif1 c mech anism of 
L-dopa action resu ltin g in such a ph eno menon ha s no t ye r been 
resolved, our findings ma y have an impli cat ion for the usefuln ess 
of L-dopa in human m alig nant melan o ma therapy !I tl !. 
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